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In Brief
Stewart et al. now find that Ewing sar-
coma cells are defective in DNA damage
repair and sensitive to PARP inhibitors.
The schedule of irinotecan used in pe-
diatric patients is well tolerated and
can potentiate PARP-inhibitor-mediated
killing of Ewing sarcoma cells in vivo.
These data raise the possibility that
PARP inhibitors may be combined with
irinotecan and temozolomide for the
treatment of Ewing sarcoma.
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Ewing sarcoma (EWS) is a tumor of the bone and soft
tissue that primarily affects adolescents and young
adults. With current therapies, 70% of patients with
localized disease survive, but patients with metasta-
tic or recurrent disease have a poor outcome. We
found that EWS cell lines are defective in DNA break
repair and are sensitive to PARP inhibitors (PARPis).
PARPi-induced cytotoxicity in EWS cells was 10- to
1,000-fold higher after administration of the DNA-
damaging agents irinotecan or temozolomide. We
developed an orthotopic EWS mouse model and
performed pharmacokinetic and pharmacodynamic
studies using three different PARPis that are in clin-
ical development for pediatric cancer. Irinotecan
administered on a low-dose, protracted schedule
previously optimized for pediatric patients was an
effective DNA-damaging agent when combined
with PARPis; it was also better tolerated than combi-
nations with temozolomide. Combining PARPis with
irinotecan and temozolomide gave complete and
durable responses in more than 80% of the mice.
INTRODUCTION
Ewing sarcoma (EWS) is the second most common bone tumor
in children and adolescents; approximately 250 new cases are
diagnosed each year in the US (Howlader et al., 2013). Most
EWS tumors have a translocation involving the EWS gene on
chromosome 22 and the FLI gene on chromosome 11 (Delattre
et al., 1992). The EWS-FLI translocation is an important driver
of tumorigenesis in EWS (Lessnick and Ladanyi, 2012). Patients
with recurrent or metastatic disease have a poor outcome (Gran-
owetter et al., 2009; Stahl et al., 2011). Recent clinical trials in
relapsed disease have shown that the combination of irinotecanC(IRN) and temozolomide (TMZ) is active in EWS, and these drugs
are now used in combination with other agents such as temsiro-
limus (Bagatell et al., 2011).
EWS cell lines are sensitive to the poly-ADP ribose polymer-
ase inhibitor (PARPi) olaparib, and this sensitivity is selective
for EWS cell lines (Brenner et al., 2012; Garnett et al., 2012).
Olaparib sensitivity depends on the EWS-FLI translocation,
suggesting a direct mechanistic connection between PARP inhi-
bition by olaparib and the mechanism of transformation by
EWS-FLI (Brenner et al., 2012; Garnett et al., 2012). Brenner
et al. also showed that the EWS-FLI1 fusion protein interacts
with PARP1 and proposed a positive-feedback loop involving
both proteins (Brenner et al., 2012). High levels of PARP1
expression are correlated with increased sensitivity to PARPis
(Byers et al., 2012; Pettitt et al., 2013; Bajrami et al., 2014),
consistent with a ‘‘trapping’’ mechanism whereby the inhibitor
acts as a poison to stabilize a PARP-DNA complex (Murai
et al., 2012). Furthermore, EWS cell lines express high levels of
Schlafen-11 (SLFN11), a putative DNA/RNA helicase whose
expression is positively correlated with increased sensitivity to
Topoisomerase I inhibitors (Topo1i) and other DNA-damaging
agents, but not protein kinase inhibitors or tubulin poisons (Bar-
retina et al., 2012; Zoppoli et al., 2012). For BRCA-deficient
breast cancer and ovarian cancer, PARPis are combined with
DNA-damaging agents to potentiate selective tumor-cell killing
(Ashworth, 2008; Bryant et al., 2005; Farmer et al., 2005; Fong
et al., 2009; Tutt et al., 2005).
In this study, we tested the cytotoxic activity and in vivo effi-
cacy of three different PARPis (BMN-673, olaparib, veliparib) in
combination with IRN and TMZ. Both TMZ and IRN potentiated
PARPi-mediated killing of EWS cells, but at least a 1,000-fold
higher concentration of TMZ was required to achieve the same
level of potentiation as that achieved with IRN. We performed
in vivo plasma and tumor pharmacokinetic (PK) experiments in
parallel with pharmacodynamics (PD) studies for each PARPi
to determine themurine-equivalent dose (MED) andwhether suf-
ficient levels of drug can be reached in the tumor to mediate tu-
mor-cell killing. The data were used to design preclinical phase I,ell Reports 9, 829–840, November 6, 2014 ª2014 The Authors 829
II, and III studies to test 15 drug combinations incorporating all
three PARPis with IRN, TMZ, or both.
RESULTS
EWS Cells Are Defective in DNA Break Repair
An analysis of the Cancer Cell Line Encyclopedia indicates that
EWS behaves as an outlier and shows high levels of both
PARP1 and SLNF11 compared to other cancers, including oste-
osarcoma (OS), another form of bone cancer (Barretina et al.,
2012). Because high levels of SLFN11 expression can increase
sensitivity to DNA-damaging agents (Zoppoli et al., 2012), we
reasoned that EWS might be deficient in DNA damage repair.
We performed quantitative PCR (qPCR) using TaqMan probes
for 46 DNA repair genes and confirmed the downregulation of
BRCA1, GEN1, and ATM; in addition, several other genes in
EWS cell lines were downregulated relative to their levels in OS
cell lines and OS orthotopic xenografts (Figures S1). Gene
expression array data from primary EWS and OS tumors were
consistent with our qPCR data and confirmed higher levels of
PARP1 and SLFN11 in EWS (Table S1).
To monitor DNA damage in individual cells, we performed a
single-cell alkali gel electrophoresis (comet) assay using an OS
cell line (U2OS) and ES-8 EWS cells (Figure 1A). Thirty minutes
after 10 Gy ionizing radiation (IR) exposure, the tail moment
significantly increased for both cells (Figures 1B and 1C). How-
ever, 11 hr after IR exposure, the tail moment in the OS line
was restored to basal levels, but that ES-8 EWSwas not (Figures
1B and 1C). To analyze the contribution of PARP, we performed
a similar experiment in the presence of olaparib, veliparib, and
BMN-673 at two concentrations (1 or 10 mM). At 10 mM olaparib
and 1 or 10 mM BMN-673, the basal level of DNA damage after
12 hr of exposure to the PARPi was elevated in ES-8, especially
for BMN-673 (Figures 1D–1G). This DNA repair defect was even
more pronounced when the cells were exposed to 10 Gy IR (Fig-
ures 1D–1G).
To independently validate these data, we performed g-H2AX
immunostaining analysis on ES-1, ES-6, ES-8, EW-8, U2OS,
and SAOS cells. The basal proportion of cells that were g-
H2AX+ and the distribution of g-H2AX+ foci per nucleus were
similar across the EWS and OS cell lines (Figure S1). All cell lines
showed rapid g-H2AX localization to foci with double-strand
DNA (dsDNA) breaks after exposure to 5 Gy IR (Figure S1). To
determine whether any defect in the repair of the dsDNA breaks
occurred after IR exposure, we performed a time course exper-
iment. Cells were exposed to 5 Gy IR, and then, at 5 min, 2 hr,
8 hr, and 24 hr, the proportions of g-H2AX+ cells (>20 foci/cell)
were scored. In the OS cell line, the proportion of g-H2AX+
decreased at 2 hr after IR exposure; by 8 hr, the cells were indis-
tinguishable from the original cell population. The resolution of g-
H2AX+ foci was significantly slower for the EWS cell line (p <
0.01; Figure 1H). To determine whether exposure to PARPis
further delays the repair of IR-induced dsDNA breaks, we per-
formed a similar experiment in the presence of olaparib, veli-
parib, or BMN-673 (Figure S1). The number of g-H2AX+ cells
was significantly increased at 24 hr after IR exposure in the pres-
ence of PARPis (p < 0.01; Figure S1). Together, these data sug-
gest that EWS cell lines are defective in DNA repair.830 Cell Reports 9, 829–840, November 6, 2014 ª2014 The AuthorsDNA-Damaging Agent and PARPi Cytotoxicity in
EWS Cells
IRN and TMZ are used in combination to treat recurrent EWS
(Casey et al., 2009), and both drugs induceDNAdamage through
distinct mechanisms (Figure 2A) (Hsiang et al., 1989; Quiros
et al., 2010). We performed dose-response experiments mea-
suring the cytotoxicity of SN-38 (the active metabolite of IRN),
TMZ, BMN-673, olaparib, and veliparib in eight Ewing sarcoma
cell lines (ES-1, ES-4, ES-6, ES-7, ES-8, EW-8, RD-ES, and
SK-ES1), three OS cell lines (SAOS2, SAOS2LM7, and U2OS),
and five OS xenografts (MAST22, MAST38, OS39R, OS43, and
OS45).The EWS cell lines were chosen to reflect diversity in
EWS-FLI1 translocation type, p53 status, and STAG2 status
(Supplemental Information). At 72 hr of exposure, EW-8, ES-8,
and ES-1 cells were sensitive to BMN-673 and olaparib, and,
at 144 hr, all EWS cell lines except ES-6were sensitive to all three
PARPis (Figures 2B–2E and S2; Table S2), though veliparib ac-
tivity was marginal. ES-6 cells, which have a nonfunctional
EWS-FLI1 translocation, were reported to be resistant to ola-
parib at 72 hr but had some sensitivity at later time points in col-
ony assays (Garnett et al., 2012). In our analysis, ES-6 cells were
resistant to all three PARPis at 72 hr and to BMN-673 and veli-
parib at 144 hr and had significantly lower potency for olaparib
and SN-38 compared to other EWS cell lines (Table S2). At
144 hr, all EWS cell lines tested excluding ES-6 had EC50
<10 nM for SN-38 and >100 mM for TMZ. In contrast to EWS
cells, OS cells showed little sensitivity to any of the compounds
tested. Only one compound had an EC50 <100 nM: SN-38 in
SAOS2 (Table S2).
To determine whether sensitivity to PARPis depends on
the expression of PARP1, we knocked down PARP1 protein in
ES-8 cells with a small interfering RNA (siRNA) (Murai et al.,
2012) (Figures 2F–2J). For each drug, PARPi sensitivity was
reduced when PARP1 expression was knocked down relative
to a control siRNA, consistent with the PARP trapping mecha-
nism (Murai et al., 2012, 2014). Indeed, PARP trapping potential
followed the same trend observed in the cytotoxicity assay
BMN-673 > olaparib > veliparib (Figure S2).
Development of an Orthotopic EWS Xenograft Model
To generate an EWS orthotopic xenograft, we developed a
method for injecting EWS cell lines or primary human tumor cells
into the bone marrow of the femur of immunocompromised mice
(Supplemental Information). Briefly, cells are resuspended inMa-
trigel at 100,000 cells/ml and drawn up in a Hamilton syringe with
a 25 G needle. The patella and ligaments of the knee are laterally
displaced, and the needle is inserted into the intercondylar fossa
by using a closed technique (Figures 3A–3F). Early signs of
engraftment include periosteal elevation on X-ray images, fol-
lowed by local tumor cell invasion, and hair-on-end appearance
(Figure 3G), as seen in patients with EWS. The soft-tissue fea-
tures of EWS orthotopic xenografts can be visualized by MRI
(Figure 3H), and tumor calcification and accompanying alter-
ations in femoral architecture can be monitored via micro-CT
(Figure 3I). We also tested two positron emission tomography
(PET) tracers (F18-deoxyglucose and C11-methionine); C11-
methionine provided superior sensitivity and signal-to-noise for
the orthotopic EWS xenografts (Figures 3J–3M; data not shown).
Figure 1. EWS Cell Lines Are Defective in dsDNA Break Repair
(A) Representative image of single-cell alkali electrophoresis with genomic DNA is shown in red; the tail moment is indicated.
(B and C) Comet data for U2OS cells (B) or ES-8 cells (C) prior to exposure to 10 Gy IR (untreated), 30 min after treatment, or 11 hr after treatment. The red line
indicates the mean.
(D–G) Comet data for cells treated with 1 or 10 mM PARPi before and 12 hr after exposure to 10 Gy IR.
(H) Micrographs of U2OS and ES-8 nuclei (blue) stained for g-H2AX (red). Scale bars, 1 mm. The proportion of g-H2AX+ cells (>20 foci/nucleus) are shown in the
histograms to the right of the micrographs. Each bar represents the mean ± SD of duplicate scoring.Tumor growth surrounding the femur (Figure 3N) and tumor his-
tology (Figures 3O and 3P) of the orthotopic tumors were very
similar to EWS tumors in patients.
In Vivo PK and PD of Veliparib, Olaparib, and BMN-673
To determine the murine equivalent dose (MED) and the level of
tumor penetration of the three PARPis, we measured drug con-
centration in the plasma and tumors of CD1-nude mice with or-
thotopic xenografts at time points ranging from 30 min to 24 hr
(Figure S3). We estimated the plasma area under the concentra-
tion-time curve (AUC) for each drug and compared those data toCthe AUC from plasma PK data in patients (Figure S3; Supple-
mental Information). Our data suggest that the most appropriate
dose for twice-daily oral administration in mice is 12.5 mg/kg ve-
liparib, 50 mg/kg olaparib, and 0.125 mg/kg BMN-673 (Supple-
mental Information). At 12 hr after dosing, concentration of at
least 0.05 mM veliparib, 0.09 mM olaparib, and 0.015 mM BMN-
673 were achieved in the orthotopic tumor (Figure S3).
Next, we combined the in vivo tumor pharmacokinetic data
with the cytotoxicity data for each PARPi in combination with
SN-38 or TMZ using a modified response surface model (RSM)
approach (Figure S3; Supplemental Information). A total of sevenell Reports 9, 829–840, November 6, 2014 ª2014 The Authors 831
Figure 2. Potentiation of PARPi Cytotoxicity with IRN and TMZ
(A) Model of DNA damage and synthetic lethality for the combination of PARPis with TMZ or IRN.
(B–D) Dose response for EW-8, ES-6, and SAOS cells 72 hr after exposure to each indicated PARPi. Curves fit using data pooled from two biological replicates,
each with at least three technical replicates.
(E) A similar experiment was performed at 144 hr.
(F and G) (F) Immunoblot with quantification (G) of the knockdown of PARP1 in EW-8 cells transfected with a PARP1 siRNA.
(H–J) Dose response for BMN-673, olaparib, and veliparib in EW-8 cells at 72 hr with (solid line) andwithout (dashed line) knockdown of PARP1. Each data point is
the mean ± SD of triplicate wells.
(K–P) Potentiation of PARPi in the presence of increasing concentrations of TMZ and SN-38. Curves were generated by taking horizontal slices through the
efficacy surface estimated using the response surface model (RSM) approach.
832 Cell Reports 9, 829–840, November 6, 2014 ª2014 The Authors
Figure 3. Development and Characterization of an Orthotopic EWS Tumor Model
(A) Diagram of the injection procedure.
(B–D) X-ray images of a mouse leg showing the injection procedure before, during, and after injection.
(E and F) Hematoxylin and eosin staining of mouse femur and bone marrow after injection of EWS cells in Matrigel (yellow dashed line). Arrows indicates the
injection site.
(G) X-ray image of an orthotopic tumor with bony extensions (arrow).
(H) Transverse view of the soft-tissue and bony component of the orthotopic EWS xenograft in an MRI.
(I–M) Micro-PET/computed tomography (CT) scans using 11C-methionine. The tumor (arrow) shows accumulation of the radiotracer.
(N) Photograph of the femur removed from a mouse with a large mass from the orthotopic xenograft.
(O and P) High- and low-power images of the orthotopic tumor showing its extension from the bone to the surrounding soft tissue.drug pairs were examined (three PARPi + SN-38, three PARPi +
TMZ, and SN-38 + TMZ) in four EWS cell lines. We used
nonlinear regression to fit the observed 2D assay response sur-
face as a function of the hill equation parameters for each com-Cpound, the overall efficacy, and kappa (k), a measure of the inter-
action between the two drugs (k < 0 indicates antagonism, k = 0
indicates Loewe additivity, and k > 0 indicates synergy). In every
EWS cell line tested, the fitted k value indicated additivity orell Reports 9, 829–840, November 6, 2014 ª2014 The Authors 833
Figure 4. Preclinical Phase I/II Studies
(A) Drug-combination schedules. Yellow circles
represent the PARPi, green bars represent the TMZ
and red stars represent daily IP dosing of IRN.
(B–D) Survival of mice in the preclinical phase I trial
of each PARPi combined with IRN (I) or TMZ (T). In
some groups, TMZ was reduced by 50% (T50), 64%
(T36), or 70% (T30). For BMN-673, the dose was
reduced by 20% in one group (P80).
(E–G) Preclinical phase II data for IRN + TMZ alone
or in combination with veliparib (blue), olaparib (red),
or BMN-673 (green). Tumor burden was monitored
by Xenogen imaging.
(H–L) Representative Xenogen images for each
treatment group and photographs of the tumors
(arrows) or femurs at the end of the study.synergy for all PARPi + SN-38 or TMZ combinations. Overall, the
RSM analyses suggest that combining PARPi with either TMZ or
SN-38 will be synergistic in EWS cell lines, with a greater degree
of synergy observed for PARPi + TMZ drug pairs.
Although the sign and magnitude of the interaction between
drug pairs is important, the combined efficacy at physiologically
reasonable concentrations is more relevant when determining
the potential utility of a drug combination for in vivo application.
Using the RSM, one can predict the combined efficacy of a drug
combination at any concentration. In translocation-positive EWS
cell lines, SN-38 begins to significantly potentiate PARPi be-
tween 1 and 10 nM, whereas 10–100 mM TMZ is required for
the same level of potentiation (Figures 2K–2P). In all transloca-
tion-positive EWS cell lines, we predict that the most efficacious834 Cell Reports 9, 829–840, November 6, 2014 ª2014 The Authorsdrug combinations are: BMN 673 + SN-
38 > Olaparib + SN-38 > BMN 673 + TMZ
> all other drug pairs. In summary, our
in vitro synergy study using RSM suggests
that, although PARPi + TMZ pairs tend to
be more synergistic than PARPi + SN-38
pairs, less SN-38 is needed to achieve a
desirable level of efficacy.
To verify that the drugs penetrated the
tumor and inhibited PARP in the tumor
cells in vivo, we performed a PD assay II
(Supplemental Information). At the MED,
each of the PARPis reduced PARP activity
within 1 hr, and PARP activity was restored
over the next 6–12 hr (Figure S3). BMN-673
and olaparib sustained PARP inhibition
longer than did veliparib in vivo.
Preclinical Phase I Study
Having established that sufficient levels of
the three PARPis can be achieved in the or-
thotopic xenograft in vivo to inhibit PARP
at theMED, we initiated a preclinical phase
I trial to test the tolerability of PARPis as
single agents and in combination with
IRN, TMZ, or both. Our preclinical phase I
trials were performed in three to five femaleCD1-nude mice per treatment group for a total of four to six
courses of therapy (12–18 weeks; Figure 4A). The PARPis were
administered orally twice daily to match the dosing in patients.
Importantly, we used a low-dose, protracted schedule of IRN
(i.e., 1.25 mg/kg twice daily for 5 days (d 3 5 3 2) equivalent
to 20 mg/m2 d 3 5 3 2 in children (Furman et al., 1999; Supple-
mental Information). The pediatric dose using this d 3 5 3 2
schedule is much lower than that used in adults with cancer,
who receive 100–350 mg/m2 IRN one to three times per course
(Kummar et al., 2011; Samol et al., 2012). TMZ was initially
administered at 33 mg/kg on a d 3 5 schedule, which is equiva-
lent to 100 mg/m2 in children (Horton et al., 2007).
For veliparib, nearly all combinations were well tolerated for
four courses (12 weeks), except the veliparib + IRN + TMZ
combination (Figure 4B). In patients who do not tolerate the com-
bination of TMZ + IRN, the dose is often reduced 50% from
100 mg/m2 to 50 mg/m2 (Wagner et al., 2009). Veliparib +
IRN + TMZ (50%) was well tolerated for four courses (Figure 4B).
Similar results were obtained with olaparib (Figure 4C). The toler-
ability of TMZ was even less in combination with BMN-673 (Fig-
ure 4D). The TMZ dose had to be reduced by 70% (10 mg/kg
in mice and 30 mg/m2 in children), and the BMN-673 dose by
20% of the MED (0.1 mg/kg) to make this combination tolerable
(Figure 4D; Table S3).
Preclinical Phase II Study
To test if any of the PARPis reduce orthotopic EWS tumor growth
in vivo, we performed a preclinical phase II study. Phase II
studies are designed to provide rapid efficacy data by using a
randomized, placebo-controlled study design (Supplemental
Information).
Five groups comprising five mice per group with EW-8 or-
thotopic xenografts were used in this study. In addition to
the placebo group, we included IRN + TMZ (50%) as a control
group. The placebo group showed rapid tumor progression,
and all mice were off study by 14 days after enrollment (data
not shown). The mice in the IRN + TMZ (50%) group had stable
disease (SD) or progressive disease (PD) but no partial
response (PR) or complete response (CR) (Figures 4E–4G;
Supplemental Information). The veliparib + IRN + TMZ (50%)
group included 1 mouse with PR; the rest had SD or PD (Fig-
ure 4E). The olaparib + IRN + TMZ (50%) group had two mice
with CR, one with PR, and one with SD (Figure 4F). The BMN-
673 (80%) + IRN + TMZ (30%) group had four mice with CR
(Figure 4G). Overall, the bioluminescence from the Xenogen
imaging correlated with tumor weight and histopathologic
evaluation (Figures 4H–4L and S4; Supplemental Information).
As long as 12 weeks after cessation of treatment, mice with a
CR that received olaparib + IRN + TMZ (50%) or BMN-673
(80%) + IRN + TMZ (30%) have no evidence of tumor recur-
rence, but those with PD, SD, or PR have all progressed
rapidly (data not shown). ES-1 cells had poor engraftment
and IRN + TMZ completely eliminated the tumors (data not
shown). Mice with orthotopic ES-8 xenografted cells had
similar response to the EW-8 cells (Figure S5). The ES-6 cells
were similar to ES-1 in their poor engraftment efficiency and
slow growth but the tumors showed response to olaparib +
IRN + TMZ (50%) and BMN-673 (80%) + IRN + TMZ (50%)
(Figure S5).
The Cmax and AUC of SN-38 in mouse plasma has been re-
ported to be slightly higher than those in human plasma because
mice have higher levels of the plasma carboxylesterases that
convert IRN to SN-38 (Morton et al., 2000, 2005). To determine
whether the efficacy of IRN + PARPis in vivo was caused by
the higher Cmax or AUC of SN-38 in mice, we performed plasma
PK and efficacy studies in carboxylesterase-deficient mice that
more closely recapitulate the PK profile of SN-38 in humans
(Morton et al., 2005). As shown previously, the plasma SN-38
Cmax and AUC were slightly reduced in the carboxylesterase-
deficient mice after intraperitoneal injection of IRN (Figure S5;
Supplemental Information), but there was no effect on tumor
response (Figure S5).CPreclinical Phase III Study
Our in vitro RSM predicted that BMN-673 + IRN or BMN-673 +
TMZ would be significantly cytotoxic, olaparib + IRN may be
more efficacious than olaparib + TMZ, and that veliparib-combi-
nation chemotherapy would probably not achieve significant
in vivo efficacy at the dose and schedule used for these experi-
ments. To test these predictions and directly compare the effi-
cacy of each PARPi in combination with TMZ, IRN, or both, we
performed a double-blind, randomized, placebo-controlled pre-
clinical phase III trial. Briefly, we performed 350 intrafemoral in-
jections of luciferase-labeled ES-8 cells into female CD1-nude
mice. Over 5 weeks, the trial enrolled 274 mice and randomized
them to 15 treatment groups (Table S4). Ten mice each were
assigned to the placebo and single-agent PARPi groups;
25 mice were assigned to the BMN-673 (80%) + IRN + TMZ
(30%) group; and 20 mice each were assigned to the other
treatment groups (Table S4). All mice were assigned a mouse
medical record number at enrollment, which allowed their data
to be linked via an OpenClinica database (Supplemental
Information).
Overall survival of mice in the placebo group did not signifi-
cantly differ from that in the single-agent PARPi-treatment
groups (Figure 5A). As predicted by the RSM, of the groups
that received combinations of PARPis with TMZ, only those
that received BMN-673 + TMZ (50%) had significantly improved
overall survival (p = 0.0004, Figure 5B). The groups that received
PARPi + IRN tolerated the combinations well; responses were
significantly better in the olaparib + IRN or BMN-673 + IRN
groups than in the veliparib + IRN or TMZ + IRN groups (p =
0.0001, Figure 5C). All but one mouse in the olaparib + IRN +
TMZ (50%) or BMN-673 (80%) + IRN + TMZ (30%) groups
were alive at the end of the 12 week study (Figure 5D). All mice
that came off study due to tumor growth were classified as hav-
ing PD. Those that completed the four courses of therapy were
classified as having CR, PR, SD, or PD based on the Xenogen
thresholds used in the preclinical phase II study. The following
percentages of each group showed CR: 15% (3/20) in the veli-
parib + IRN + TMZ (50%) group, 71% (12/17) in the olaparib +
IRN + TMZ (50%) group, and 88% (14/16) in the BMN-673
(80%) + IRN + TMZ (30%) group. The Xenogen data correlated
with tumor burden and histopathology (Figures 5I–5K).
In cell culture, IRN and TMZ showed strong potentiation of ve-
liparib-mediated killing of EWS cells (Table S2). However, at the
MED of that used in pediatric brain tumor phase II studies of ve-
liparib with temozolomide (Su et al., 2014), our model predicted
and our preclinical phase II and III studies validated that the
levels of veliparib in the tumors were not sufficient to achieve
high rates of CR. The pediatric brain tumor combination
phase I trial with veliparib and temozolomide was designed to
maximize the temozolomide dose and escalate the veliparib.
However, our data presented here suggest that the opposite
may be advantageous for Ewing sarcoma. Therefore, we per-
formed additional phase I/II studies with a higher dose of veli-
parib (62.5 mg/kg twice a day 35 32) in combination with IRN
and TMZ (50%). The higher dose veliparib was well tolerated in
combination with IRN and TMZ and had efficacy similar to that
of olaparib + IRN + TMZ (50%) and BMN-673 + IRN + TMZ
(30%) (Figure S5).ell Reports 9, 829–840, November 6, 2014 ª2014 The Authors 835
Figure 5. Preclinical Phase III Study
(A–D) Survival curves for each of the 15 treatment groups.
(E–G) Tumor response for individual mice in the TMZ + IRN group and the triple-drug combinations for veliparib (blue), olaparib (red), and BMN-67e (green). The
cutoffs for progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR) are indicated by gray shading.
(H) Histogram of the proportion of CRs seen in each triple-drug treatment group.
(legend continued on next page)
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DISCUSSION
Three PARPis in combination with DNA-damaging agents
showed that PARPi-mediated cytotoxicity can be potentiated
by IRN and TMZ in vitro and in vivo. In vivo PK of veliparib, ola-
parib, and BMN-673 in plasma and tumor were used to calculate
the MEDs and demonstrate tumor penetration and PARP inhibi-
tion at clinically relevant doses in orthotopic EWS xenografts. A
preclinical phase I study revealed that combinations of PARPis
with IRN were better tolerated than those with TMZ. Further-
more, the low-dose, protracted schedule of IRN used to treat pe-
diatric patients with solid tumors (20 mg/m2 d 35 32) was well
tolerated with all three PARPis, but the TMZ dose had to be
reduced (50%–70%). The levels of all three PARPis in the tumor
were sufficient to potentiate cytotoxicity with DNA-damaging
agents but were insufficient to induce cytotoxicity on their own.
A preclinical phase II study demonstrated the efficacy of all
three PARPis in combination with IRN and TMZ, and this pro-
vided justification for a subsequent in vivo efficacy study. In a
double-blind, randomized, placebo-controlled preclinical phase
III trial, we found significant improvement in overall survival and
outcome when olaparib or BMN-673 was combined with TMZ
and IRN. Most of the mice had a CR and did not exhibit tumor
recurrence as long as 12weeks after cessation of therapy. These
data suggest that the combination of PARPis and IRN adminis-
tered in the low-dose, protracted schedule optimized for pediat-
ric patients should be considered for clinical development. A
reduced dose of TMZmay be incorporated to provide full poten-
tiation of PARP inhibition in EWS. Although veliparib was not as
active as olaparib and BMN-673 in the preclinical phase III study,
a higher dose of veliparib was well tolerated in preclinical phase I
and had efficacy comparable to olaparib and BMN-673 in a pre-
clinical phase II with IRN and TMZ.
DNA-Damaging Agents and PARPis in EWS
EWS cells express high levels of SLFN11 and PARP1 compared
to other cancers, providing a rationale for combining DNA-
damaging agents and PARPis. TMZ has been favored in the
PARPi EWS clinical trials developed to date because in adults,
camptothecins (topotecan or IRN) caused dose-limiting myelo-
suppression and diarrhea when combinedwith PARPis (Kummar
et al., 2011; Samol et al., 2012). However, the low-dose, pro-
tracted schedule and the sensitivity of EWS cells to IRN make
this camptothecin an attractive agent to combine with PARPis.
Our PK, PD, and in vitro drug-combination studies showed
that concentrations of PARPis and IRN can be achieved in vivo
at levels sufficient to potentiate PARP-mediated cytotoxicity
in vivo.
We did not test ionizing radiation in our studies, but this is
another therapy that should be considered in combination with
PARPis and DNA-damaging agents. EWS tumors are sensitive
to IR, and similar potentiation might be achieved with IR in vivo
(Lee et al., 2013). The majority of EWS cell lines have TP53 mu-(I) Representative Xenogen images of single-agent PARPis and corresponding tr
(J) Representative photographs of tumors from placebo, IRN + TMZ, single-agen
(K and L) Representative micrographs of hematoxylin-and-eosin-stained tissue
sponding triple-drug treatment groups. Scale bars in (K), 500 mm, and in (L), 100
Ctations (Tirode et al., 2014), so it is difficult to compare the sensi-
tivity of wild-type and TP53-deficient EWS cell lines to PARPis
and DNA-damaging agents. However, TP53-deficient osteosar-
coma cell lines are insensitive to those drug combinations, so
p53 status alone cannot explain the sensitivity to PARPis and
DNA-damaging agents in our study. Indeed, Oplustilova and
colleagues found that PARPis can sensitize cells to camptothe-
cin or ionizing radiation independent of p53 status in colorectal
carcinoma cells (Oplustilova et al., 2012).
Our results suggest that STAG2 status does not correlate with
sensitivity to DNA-damaging agents or PARPis in EWS, and this
has important clinical consequences. In a separate whole-
genome sequencing study, 17% of EWS tumors had inactivating
somatic mutations in STAG2, a component of the cohesin com-
plex (Tirode et al., 2014). Those data are consistent with previ-
ously published data from Solomon et al. showing that STAG2
is frequently lost in EWS (Solomon et al., 2011). Although
STAG2-deficient glioblastoma cells appear to be more sensitive
to PARPis (Bailey et al., 2014), this does not appear to be the
case in EWS. It is encouraging that the TP53;STAG2-deficient
EWS lines remain sensitive to the drug combinations because
those patients have theworst overall survival (Tirode et al., 2014).
PARP Trapping
Although it is unlikely that high PARP1 levels alone are sufficient
for conferring sensitivity to PARPis—a DNA repair defect must
also be present—we did observe that the in vitro sensitivity of
PARPis in EWS correlated with PARP trapping potential (Murai
et al., 2012, 2014). The apparent differences in PARP trapping
may be the result of differences in drug retention times. Specif-
ically, BMN-673 may be more active as a single agent because
it remains bound to PARP1 longer than olaparib or veliparib, re-
sulting in more persistent PARP-DNA adducts. This may also
contribute to its reduced tolerability. The implications of these
data are related to dosing of each PARPi: efficacy may be
improved if veliparib is dosed at a higher intensity to overcome
these differences in tumor clearance and ultimately retention of
PARP-bound drug in the tumor cells. Indeed, our preclinical
phase II study with high-dose veliparib + IRN + TMZ showed
efficacy similar to that of BMN-673 and olaparib. Similarly,
once-daily dosing of BMN-673 may be better tolerated than
twice-daily dosing without affecting PARP inhibition and effi-
cacy. Because PARPis are combined with DNA-damaging
agents to treat patients, it will be essential to balance the dosing
and schedule of the PARPis with DNA-damaging agents to
achieve maximum efficacy and tolerability.
Preclinical Testing for Pediatric Solid Tumors
Survival of patients with recurrent or metastatic EWS is among
the worst of pediatric cancers. More importantly, outcome has
not been significantly improved in 20 years. This explains the
enthusiasm for treating recurrent EWS with PARPis, once the
original discovery showed that EWS cell lines are sensitive toiple-drug treatment groups.
t PARPi groups, and corresponding triple-drug treatment groups.
sections from placebo, IRN + TMZ, single-agent PARPi groups, and corre-
mm.
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olaparib (Garnett et al., 2012). Indeed, the first clinical trial
(NCT01583543) opened within a month of that publication. How-
ever, several unanswered questions from that first study had
important implications for the clinical trial. Could the levels of ola-
parib required to kill EWS cell lines in vitro be achieved in a pa-
tient’s tumor in vivo? Could the PARPi be combined with a
DNA-damaging agent? Which DNA-damaging agent should be
used? What is the best dose and schedule for the PARPi and
the DNA-damaging agent?
In this study, we developed and optimized a comprehensive
preclinical-testing paradigm to answer these questions in
EWS. The advantage of the program presented here is that it
directly relates in vivo PK and PD to cytotoxicity in vitro and
then uses MEDs and schedules to test those predictions in an
array of systems (i.e., cell culture to relevant orthotopic EWS xe-
nografts). Also, our preclinical phase I, II, and III trials mirror the
approach used in clinical trials and provide an efficient system
to advance new therapies. However, the key of any preclinical-
testing effort is the predictive power of the preclinical results.
The data presented here predict that single-agent olaparib will
not be an effective treatment of EWS, and the efficacy of ola-
parib + TMZ may be limited by tolerability. As the ongoing trials
with BMN-673 accrue patients, we will have additional opportu-
nities to determine the predictive power of our preclinical-testing
efforts.
The drug combination results from this study, specifically the
utility of individual PARPi, should not be generalized to non-
EWS tumors in part because of the sensitivity of EWS cell lines
to IRN (Barretina et al., 2012). Also, in vivo drug efficacy is the
product of a multitude of effects beyond intrinsic cell sensitivity,
such as influence of the tumor niche, immune system, and phar-
macokinetics. Future efforts should focus on primary human
orthotopic xenografts to complement the EWS cell line data
presented here.
EXPERIMENTAL PROCEDURES
Comet Assay
Fifty thousand ES-1, ES- 6, ES-8, or U2OS cells or 100,000mesenchymal stem
cells were plated onto 12-well dishes per well. Cells were incubated for 24 hr
and then treated with Parp inhibitor: 10 mM BMN-673, 1 mM BMN-673, 10 mM
Veliparib, 1 mM Veliparib, 10 mM Oliparib, 1 mM Oliparib, or DMSO. Cells were
incubated with the inhibitor for 14 hr and then treated with 10 Gy IR or were left
untreated. Cells were incubated an additional 10 hr and then trypsinized and
collected. For unrepaired control, cells were treated 10 Gy IR and immediately
harvested. Fifty thousand cells were suspended in 30 ml PBS. Tenmicroliters of
this suspension was mixed with 200 ml of 0.5% low melting point agarose
(Sigma) and layered on CometSlides (Trevigen). Alkaline single-cell gel electro-
phoresis was performed as described previously (Benavente et al., 2013).
Animals
CD-1 nude immunodeficient mice were purchased from Charles River (strain
code 087, heterozygous). Esterase-deficient SCID mice were bred and ob-
tained from Philip Potter (St. Jude Children’s Research Hospital). This study
was carried out in strict accordance with the recommendations in the Guide
to Care and Use of Laboratory Animals of the NIH. The protocol was approved
by the Institutional Animal Care and Use Committee at St. Jude Children’s
Research Hospital. All efforts were made to minimize suffering. All mice
were bred and housed in accordance with approved IACUC protocols.
Animals were housed on a 12:12 light cycle (light on 6 a.m. off 6 p.m.) and pro-
vided food and water ad libitum.838 Cell Reports 9, 829–840, November 6, 2014 ª2014 The AuthorsDrugs Used for In Vitro Studies
Veliparib was purchased from Selleck (S1004, CAS 912444-00-9), Olaparib
was purchased from LC Labs (O-9201, CAS 763113-22-0), BMN-673 was
purchased from Abmole (BMN673, 1207456-01-6), Temozolomide was pur-
chased from Combi-Blocks (OR-2567, CAS 85622-93-1), and SN-38 was pur-
chased from (CAS 86639-52-3). The purity of all compounds was confirmed to
be R95% using LC/MS coupled with UVTWC/ELSD detection, and concen-
tration was verified using CLND if nitrogen was present in the compound.
Gene Expression Array Analysis
Microarray assays of Ewing sarcoma tumor samples (GSE37371) were
compared to osteosarcoma arrays (HGU133v2 Affymetrix arrays, M.A.D. un-
published data). The data were RMA normalized, evaluated for quality by
PCA and, after outlier removal, statistically compared using the unequal vari-
ance t test in Partek Genomics Suite 6.6. Select data known to be associated
with DNA repair were then evaluated.
qPCR Analysis
Real-time RT-PCR experiments were performed using the Applied Biosystems
7900HT Fast Real-Time PCR system and custom TaqMan Array Micro Fluidic
Cards (Life Technologies). RNA was prepared using Trizol following manufac-
turer instructions (Life Technologies, 15596018). cDNA was synthesized using
the High Capacity cDNA to RNA kit (Life Technologies, 4387406) per user in-
structions. Samples were analyzed in triplicate and normalized to ACTB2
expression levels.
Histology and Immunohistochemistry
Paraffin-embedded formalin-fixed EWS tumors were serially sectioned for
routine hematoxylin and eosin staining. Immunostaining for histochemical
analysis was done with Ki67 (ThermoShandon, cat. RM-9106) (dilution
1:200) using hematoxylin as a counterstain (1:10 dilution). Histology images
were obtained using Aperio ImageScope (Leica Biosystems).
PARP1 Knockdown
Gene-specific siRNAs (mix of four sequences) for PARP1 (ThermoScientific, L-
006656-03-0005) were transfected into ES-8 cells using Libofectamine RNAi-
MAX Reagent (Invitrogen, 13778). Cells were harvested 48 hr posttransfection
and lysed for western analysis to confirm knockdown of PARP1. Also, cells
were harvested by trypsinization, seeded onto 96-well plates at a density of
5000 cells per well in 40 ml of media. Seventy-two hours after transfection, cells
were treatedwith 0, 1, 2.5, 5, 10, 20, 50, or 100 mMOlaparib, Veliparib, or BMN-
673 in triplicate for each condition. Seventy-two hours after addition of PARPi,
cells were analyzed for cellular activity using Cell Titer Glo (Promega, G7570).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.09.028.
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